Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

FOSACORD 70 TABLET 70 MG [SIN16511P]

Active ingredients: SODIUM ALENDRONATE TRIHYDRATE EQV. ALENDRONIC ACID

View product's general information
Last updated on 9 October 2026

Product Info

FOSACORD 70 TABLET 70 MG

[SIN16511P]

Product information

Active Ingredient and Strength

SODIUM ALENDRONATE TRIHYDRATE EQV. ALENDRONIC ACID - 70 MG

Dosage Form

TABLET

Manufacturer and Country

INTAS PHARMACEUTICALS LIMITED - INDIA

Registration Number

SIN16511P

Licence Holder

ACCORD HEALTHCARE PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

M05BA04

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

iv. Therapeutic Indication:

Alendronate Sodium is indicated for the treatment of osteoporosis in postmenopausal women.

For the treatment of osteoporosis, Alendronate Sodium reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures).

Alendronate Sodium is indicated for the treatment of osteoporosis in men.

The optimal duration of use of bisphosphonates for the treatment of osteoporosis has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis.

Dosing

v. Dosage and Administration:

Alendronate Sodium must be taken at least one-half hour before the first food, beverage, or medication of the day with plain water only. Other beverages (including mineral water), food, and some medications are likely to reduce the absorption of Alendronate Sodium (see drug interactions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

To facilitate delivery to the stomach and thus reduce the potential for esophageal irritation, Alendronate Sodium should only be swallowed upon arising for the day with a full glass of water and patients should not lie down for at least 30 minutes and until after their first food of the day. Alendronate Sodium should not be taken at bedtime or before arising for the day. Failure to follow these instructions may increase the risk of esophageal adverse experiences (see precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Patients should receive supplemental calcium and vitamin D, if dietary intake is inadequate (see precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

No dosage adjustment is necessary for the elderly or for patients with mild-to-moderate renal insufficiency (creatinine clearance 35 to 60 mL/min). Alendronate Sodium is not recommended for patients with more severe renal insufficiency (creatinine clearance < 35 mL/min) due to lack of experience.

Treatment of osteoporosis in postmenopausal women and in men:

The recommended dosage is one 70 mg tablet once weekly.

vi. Method of administration

Alendronate Sodium must be taken at least one-half hour before the first food, beverage, or medication of the day with plain water only.

Contraindications

vii. Contraindications:

  • Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia.

  • Inability to stand or sit upright for at least 30 minutes.

  • Hypersensitivity to any component of this product.

  • Hypocalcemia (see Precautions – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).